Published in Infect Immun on February 01, 2006
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Recent developments for Pseudomonas vaccines. Hum Vaccin (2011) 0.91
Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization. BMC Microbiol (2010) 0.86
A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother (2013) 0.85
Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother (2014) 0.81
An Inactivated Antibiotic-Exposed Whole-Cell Vaccine Enhances Bactericidal Activities Against Multidrug-Resistant Acinetobacter baumannii. Sci Rep (2016) 0.78
Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection. Hum Vaccin Immunother (2012) 0.77
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis (2000) 4.93
Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis (1995) 1.63
Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med (1987) 1.59
Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. Arch Dis Child (1984) 1.35
Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect Immun (1994) 1.23
A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. Immunology (1994) 1.20
Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine (2001) 1.12
Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect Immun (1995) 1.12
Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Am Rev Respir Dis (1986) 1.06
Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins. J Immunol (1991) 1.05
Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet (1986) 1.05
Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4. Infect Immun (1993) 1.04
Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. Am Rev Respir Dis (1991) 1.01
Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. J Clin Invest (1989) 0.98
Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89). J Infect Dis (2000) 0.95
IgA and IgG antibodies against surface antigens of Pseudomonas aeruginosa in sputum and serum from patients with cystic fibrosis. Acta Pathol Microbiol Scand C (1979) 0.91
Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae. Med J Aust (1990) 0.89
A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J Med Microbiol (2000) 0.88
Increased Fc alpha R expression and IgA-mediated function on neutrophils induced by chemoattractants. J Immunol (1993) 0.86
Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS (1992) 0.86
A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Aust N Z J Med (1991) 0.85
Specific protection against acute bronchitis associated with nontypeable Haemophilus influenzae. J Infect Dis (1992) 0.85
Pseudomonas aeruginosa: the potential to immunise against infection. Expert Opin Biol Ther (2005) 0.84
Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev (2003) 0.81
Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev (2000) 0.79
Immunity to respiratory Pseudomonas aeruginosa infection: the role of gut-derived T helper cells and immune serum. Adv Exp Med Biol (1995) 0.79
Identification of outer membrane proteins as target antigens of Pseudomonas aeruginosa Homma serotype M. Clin Diagn Lab Immunol (1995) 0.77
IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. APMIS Suppl (1996) 0.77
Vaccine strategies against Pseudomonas aeruginosa infection in the lung. Behring Inst Mitt (1997) 0.77
Permeability or local production of immunoglobulins and other inflammatory proteins in asthma. Eur Respir J Suppl (1991) 0.77
Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity. Infect Immun (2005) 1.00
Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood (2004) 0.93
Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest (2009) 0.92
Acute exacerbations in COPD and their control with oral immunization with non-typeable haemophilus influenzae. Front Immunol (2011) 0.77
Evidence-supported rehabilitation of patellar tendinopathy. N Am J Sports Phys Ther (2010) 0.77
Selective reduction of anti-Helicobacter pylori IgG subclass antibody in gastric carcinoma. J Gastroenterol Hepatol (2005) 0.76
A vaccine to prevent exacerbations in COPD. Med J Aust (2011) 0.75
Mucosal immunology down under: Special Interest Group in Mucosal Immunology workshop, Australasian Society for Immunology, Sydney, Australia, 2 December 2007. Immunol Cell Biol (2008) 0.75